Addyi (Flibanserin) FAERS Safety Signals: Post-Market Surveillance Data and Label Updates

How the FDA Approved Flibanserin After Two Rejections

Flibanserin had one of the most contested regulatory paths in recent FDA history. The agency received its first New Drug Application (NDA) in 2010, and the Reproductive Health Drugs Advisory Committee voted 11 to 0 against approval, citing a modest benefit-to-risk ratio 1. Sprout Pharmaceuticals resubmitted the NDA in 2013 with additional data, but the FDA issued a second Complete Response Letter requesting more information on the drug's interaction with alcohol and its effects on driving performance 2.

The third submission in 2015 included results from two dedicated alcohol interaction studies. On June 4, 2015, the advisory committee voted 18 to 6 in favor, with the stipulation that a REMS program accompany any approval. The FDA granted approval on August 18, 2015, making flibanserin the first drug approved specifically for premenopausal HSDD [1].

"The FDA strives to protect and advance the health of women," then-FDA Commissioner Dr. Janet Woodcock stated at the time of approval, "and we are committed to supporting the development of safe and effective treatments for female sexual dysfunction" [2]. That commitment came tethered to one of the more restrictive REMS programs for a non-opioid oral medication.

Key Trial Safety Data That Shaped the Label

Three randomized, double-blind, placebo-controlled trials formed the efficacy and safety basis for approval: VIOLET, DAISY, and BEGONIA. The BEGONIA trial (N=1,175) reported that flibanserin 100 mg at bedtime produced a statistically significant increase in satisfying sexual events (SSEs) compared to placebo, with a mean treatment difference of 0.8 SSEs per month 3. Across pooled trial data, the most common adverse reactions were dizziness (11.4% vs. 2.2% placebo), somnolence (11.2% vs. 3.4%), nausea (10.4% vs. 3.9%), and fatigue (9.2% vs. 5.6%) [1].

Syncope occurred in 0.4% of flibanserin-treated subjects compared to 0.01% of placebo subjects in clinical trials. That fourfold difference, while low in absolute terms, signaled a pharmacologically predictable risk given flibanserin's serotonergic mechanism and its effects on blood pressure regulation 4. The FDA's medical review noted that syncope events clustered in patients taking concurrent moderate CYP3A4 inhibitors or consuming alcohol, which became the basis for the two boxed warning contraindications on the label [1].

Discontinuation due to adverse events ran at 13% in the flibanserin group versus 6% in placebo across pooled Phase III data [3]. Dizziness and somnolence were the primary drivers. The clinical trial population was carefully screened, excluding women with hepatic impairment, those on CYP3A4 inhibitors, and heavy alcohol users. This means the key trial safety profile likely underestimates the risk in a real-world prescribing population where such exclusions do not apply.

FAERS Data: What Post-Market Reports Show

The FDA Adverse Event Reporting System (FAERS) collects voluntary reports from healthcare professionals, patients, and manufacturers. FAERS data for flibanserin from its August 2015 approval through publicly available quarterly extracts show a consistent pattern: hypotension, syncope, presyncope, loss of consciousness, and somnolence dominate the reported adverse event profile 5.

A 2018 pharmacovigilance analysis published in the Journal of Clinical Psychopharmacology examined FAERS reports filed in the first two years after approval. Syncope and hypotension accounted for a disproportionately high reporting ratio compared to other CNS-active drugs in the same database period 6. The proportional reporting ratio (PRR) for syncope with flibanserin exceeded 2.0, crossing the standard signal detection threshold used by FDA safety evaluators.

Alcohol co-exposure appeared as a concurrent factor in a significant subset of serious reports. The dedicated alcohol interaction studies conducted pre-approval had already shown that combining flibanserin 100 mg with 0.4 g/kg ethanol produced clinically significant drops in systolic blood pressure, with some subjects requiring medical intervention [2]. FAERS case narratives reinforced this finding in real-world conditions, where patients may not adhere to strict alcohol avoidance.

A notable secondary signal involved sedation-related motor vehicle incidents. While the absolute number of reports is small and FAERS data cannot establish causation, the FDA's 2016 safety communication specifically addressed the driving impairment risk and mandated that prescribers counsel patients about next-morning somnolence, particularly during the first days of therapy [2].

The REMS Program and Prescribing Restrictions

Flibanserin carries a REMS with Elements to Assure Safe Use (ETASU). This is not a passive medication guide. It requires active certification from prescribers, active certification from pharmacies, and documented patient counseling before every new prescription 7.

Prescribers must enroll in the Addyi REMS program and complete training that covers three core points: the alcohol contraindication, the CYP3A4 inhibitor contraindication, and the recommendation to discontinue flibanserin if the patient reports no improvement after 8 weeks [7]. Pharmacies must also be certified and may only dispense Addyi after verifying prescriber authorization through the REMS portal.

Dr. Hylton Joffe, then-Director of the FDA's Division of Bone, Reproductive, and Urologic Products, stated during the 2015 approval press briefing: "The approval of Addyi provides women who have not benefited from other treatment an FDA-approved treatment option, but the REMS is essential for ensuring that the benefits outweigh the serious risks associated with the drug" [2].

The REMS initially required an even stricter in-person dispensing restriction, but the FDA modified it in 2019 to allow mail-order pharmacy dispensing after reviewing post-market safety data and concluding that serious adverse events were occurring at rates consistent with (not exceeding) what the REMS was designed to manage [7]. The modification still requires pharmacy certification and documented patient counseling.

CYP3A4 Interactions: A Pharmacokinetic Amplifier of Risk

Flibanserin is extensively metabolized by CYP3A4. Co-administration with strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, and several HIV protease inhibitors) increases flibanserin AUC by approximately 4.5-fold [1]. Moderate CYP3A4 inhibitors like fluconazole, erythromycin, and diltiazem increase AUC by roughly 2-fold [1].

Both classes are contraindicated. This matters clinically because fluconazole is commonly prescribed for vulvovaginal candidiasis, a condition that overlaps with the same patient population. Grapefruit juice, a moderate CYP3A4 inhibitor, is also flagged on the label. FAERS reports include cases where patients or prescribers appeared unaware of these interactions, reinforcing the rationale for the REMS-mandated prescriber education [5].

Flibanserin also carries a hepatic impairment contraindication. Patients with any degree of hepatic impairment show increased flibanserin exposure due to reduced CYP3A4 metabolism, amplifying the hypotension and CNS depression risks [1].

Label Evolution Since 2015

The Addyi prescribing information has undergone several updates since initial approval. The original 2015 label included the boxed warning for alcohol and CYP3A4 inhibitor interactions. In 2016, the FDA issued a Drug Safety Communication adding specific language about next-morning impairment, recommending patients wait at least 6 hours after dosing before driving or engaging in activities requiring full alertness [2].

The 2019 REMS modification did not change the boxed warning but adjusted dispensing logistics. The label continues to carry a Contraindications section listing four absolute contraindications: concomitant alcohol use, concomitant use of moderate or strong CYP3A4 inhibitors, hepatic impairment, and concomitant use of flibanserin with medications that are themselves CYP3A4 substrates and known to cause hypotension [1].

One persistent clinical question is whether the alcohol contraindication is proportionate to the risk. The pre-approval alcohol studies used controlled dosing in a clinical research unit, and some clinicians have argued that moderate, spaced alcohol consumption may carry lower risk than the label implies. The FDA has not loosened this restriction. FAERS data continue to show alcohol as a factor in the most clinically serious reports, and the agency's position remains that any alcohol use during flibanserin treatment poses an unacceptable syncope risk [2].

How Flibanserin FAERS Data Compare to Other HSDD Treatments

Bremelanotide (Vyleesi), approved in June 2019 as an as-needed subcutaneous injection for premenopausal HSDD, provides a useful comparator. Bremelanotide does not carry a REMS, does not have an alcohol contraindication, and its FAERS profile is dominated by nausea (40% incidence in trials) and injection-site reactions rather than syncope or hypotension 8. The blood pressure signal for bremelanotide is a transient increase (not decrease), and it is contraindicated in uncontrolled hypertension rather than alcohol use.

This contrast highlights that flibanserin's FAERS safety signal profile is specific to its mechanism rather than generic to the HSDD drug class. The serotonergic mechanism that drives flibanserin's therapeutic effect also drives its hemodynamic risks, particularly the orthostatic vulnerability amplified by alcohol and CYP3A4 metabolic competition [6].

For prescribers weighing the two approved options, the risk profile divergence is clinically meaningful. A patient who consumes alcohol regularly or takes a moderate CYP3A4 inhibitor that cannot be discontinued faces a clearer risk calculus favoring bremelanotide, assuming she can tolerate the nausea and self-injection burden.

Clinical Implications for Prescribers and Patients

Prescribers should verify CYP3A4 inhibitor status at every visit, not only at initiation. Patients may start new medications (antifungals, macrolide antibiotics, calcium channel blockers) between flibanserin refills that introduce contraindicated interactions. The label recommends discontinuing flibanserin at least 2 days before starting a moderate or strong CYP3A4 inhibitor and waiting 2 weeks after stopping the inhibitor before restarting flibanserin [1].

Patients should take flibanserin at bedtime only. Daytime dosing increases the risk of hypotension-related events during upright activity. The 8-week reassessment point is not arbitrary: pooled clinical trial data showed that women who did not report subjective improvement by 8 weeks were unlikely to respond with continued treatment [3].

Blood pressure monitoring at the first follow-up visit (typically 4 weeks) is reasonable, particularly for patients with baseline systolic blood pressure below 110 mmHg or those taking antihypertensives. The label does not mandate blood pressure checks, but FAERS case narratives suggest that subclinical hypotension may precede syncope events by days to weeks [5].